Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia''s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute.
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia''s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute.